Tag Archive for: pharmaceutical industry

Ashfield Event Experiences, part of Inizio Engage XD, has teamed up with the IPCAA (International Pharmaceutical Congress Advisory Association) to address how healthcare provider (HCP) behaviors and attitudes towards medical congresses and conventions have been impacted by the return of in-person events.

Most leading U.S. patient advocacy organizations have board members or senior leaders with ties that raise questions about industry influence over their policies, according to a research letter published Monday in JAMA Internal Medicine.

Brussels on Wednesday published a long-awaited draft of its proposed overhaul of laws governing the European Union’s pharmaceuticals industry, setting up a tussle with drugmakers which warn they will invest and innovate elsewhere.

British drugmaker GSK on Wednesday warned that the overhaul of laws governing the EU’s pharmaceuticals industry risks forcing companies to invest and innovate elsewhere, which would hurt EU efforts to improve access to medicines.

Governments should invest in vaccines for all strains of influenza virus that exist in the animal kingdom as an insurance policy in case of an outbreak in humans, the incoming chief scientist at the World Health Organization said on Monday.

Martin Shkreli on Friday urged a U.S. judge not to hold him in civil contempt for failing to provide federal and state regulators with information to determine whether he is violating a lifetime ban from working in the pharmaceutical industry.

The pharmaceutical industry is expected to spend more than $3 billion on artificial intelligence by 2025 – up from $463 million in 2019. AI clearly adds value, but advocates say it is not yet living up to its potential.

Much of the global pharmaceutical and biotech industry has yet to set any targets for reducing carbon emissions in line with the Paris Agreement, a new analysis has found, despite the biggest companies in the sector leading the way.

Drugmakers are launching new medicines at record-high prices this year, a Reuters analysis has found, highlighting their pricing power even as Congress moves to cut the $500 billion-plus annual bill for prescription drugs in the United States.